Name
RF5-03 (Span) OlympiaN: Phase 2 study of neoadjuvant olaparib ± durvalumab in BRCA+ early HER2- breast cancer - Commentary by Fernando Petracci, MD, MSc, PhD
Date & Time
Thursday, December 4, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL